Merck Animal Health To Acquire Harrisvaccines - Quick Facts

(RTTNews) - Merck Animal Health and Harrisvaccines, Inc., announced they have entered into an agreement under which Merck Animal Health will acquire Harrisvaccines, a privately-held company that develops, manufactures and sells vaccines for food production and companion animals.

Harrisvaccines offers innovative technology and an important portfolio of vaccines, with a focus on production animals. The company has a unique RNA Particle technology which represents a breakthrough in vaccine development. It also has a highly versatile production platform able to target a wide range of viruses and bacteria.

In September 2015, Harrisvaccines received a conditional approval for a Eurasian H5 subtype avian influenza vaccine and was subsequently awarded a contract by the United States Department of Agriculture's Animal and Plant Health Inspection Service to produce the vaccine.